Background/Aims Previous studies have identified a substantial degree of agreement between the non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) populations, but the same notion may not apply to normal-weight patients with a lower cardiometabolic risk burden. This study aims to investigate the cardiometabolic risk factor (CMRF) distributions between normal-weight and overweight/obese MASLD, the agreement between historical NAFLD and MASLD, and to compare the risk of liver-related events (LREs) and all-cause mortality in normal-weight versus overweight or obese MASLD.
Methods This study included participants with steatotic liver disease (SLD) from five cohorts in China (Hong Kong), South Korea, and the United States. Participants were recruited from settings including both hospitals and communities. Individuals were classified into normal-weight and overweight/obese groups.
Results This study included 33,793 participants with SLD from five cohorts, of whom 20,893 and 20,701 patients met the diagnosis of NAFLD and MASLD, respectively. Normal-weight patients with NAFLD demonstrated a lower CMRF distribution compared to those with overweight/obese NAFLD. In the community-based cohorts, the proportions with 0 CMRF ranged from 9.0 to 26.7% among normal-weight NAFLD patients, representing the discrepancy between MASLD and NAFLD definitions. Compared with the overweight/obese MASLD, the normalweight MASLD had increased all-cause mortality (normal-weight vs. overweight/obese, 23.44 and 13.80 per 1,000 person-years; P<0.001) but not LREs (2.81 and 2.59 per 1,000 person-years; P=0.54) in the Hong Kong Clinical Data Analysis and Reporting System cohort.
Conclusions Normal-weight individuals with NAFLD demonstrated a lower distribution of CMRFs, resulting in the incomplete agreement between historical NAFLD and MASLD.
Citations
Citations to this article as recorded by
Challenges in defining MASLD in lean individuals: the impact of the Fatty Liver Index on phenotypic characterisation Sherlot Juan Song, Yiwei Liu, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip Gut.2026; : gutjnl-2026-338216. CrossRef
Xinrui Jin, Sherlot Juan Song, Jimmy Che-To Lai, Grace Lai-Hung Wong, Alice Pik-Shan Kong, Nana Peng, Xiang Xiao, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip
Clin Mol Hepatol 2026;32(1):353-367. Published online December 1, 2025
Background/Aims Previous studies suggest that hypothyroidism is associated with metabolic dysfunction-associated steatotic liver disease (MASLD) and its histological severity, but clinical outcome data are largely lacking. We aimed to study the impact of hypothyroidism on liver-related events (LREs).
Methods Patients with MASLD were identified from a territory-wide registry in Hong Kong during 2000–2024. Thyroid status was determined using diagnosis codes and thyroid function tests. The primary outcome, LRE, was defined as a composite of hepatic decompensation, hepatocellular carcinoma, liver transplantation, and liver-related death.
Results A total of 20,478 patients with MASLD were included in the final analysis (mean age 56.4±13.2 years; 43.9% male). At baseline, 18,178 (88.8%) patients were euthyroid, 598 (2.9%) were hyperthyroid, and 1,702 (8.3%) were hypothyroid. Compared with euthyroid patients, both hyperthyroidism and overt hypothyroidism were associated with cirrhosis. At a median follow-up of 4.8 years, 179 patients developed LREs, and 26 died from liver disease. Compared with patients with normal serum thyroid-stimulating hormone (TSH) levels of 0.4–4 mIU/L, those with subclinical (4–10 mIU/L; adjusted time-dependent cause-specific hazard ratio [aCSHR], 2.49; 95% CI, 1.51–4.13) and overt hypothyroidism (>10 mIU/L; aCSHR, 4.91; 95% CI, 1.56–15.47) had an increased risk of LREs. Time-dependent, but not baseline, TSH and thyroid status were associated with LRE risk.
Conclusions Subclinical and overt hypothyroidism are associated with an increased risk of LREs in a dose-dependent manner. The association with time-dependent but not baseline thyroid status underscores the importance of thyroid monitoring and suggests that correction of hypothyroidism may mitigate LRE risk.
Citations
Citations to this article as recorded by
Hypertension and long-term adverse clinical outcomes in MASLD: Sensitivity analyses for unmeasured or uncontrolled confounding Guiying Gao, Xiuhong Wang, Ruizhe Huang, Jing Cao Journal of Hepatology.2026;[Epub] CrossRef
Not just fat: muscle also matters in metabolic dysfunction-associated steatotic liver disease (MASLD) Xinyan Zong, Grace Lai-Hung Wong Hepatology International.2026;[Epub] CrossRef
In managing metabolic dysfunction-associated steatotic liver disease, which affects over 30% of the general population, effective noninvasive biomarkers for assessing disease severity, monitoring disease progression, predicting the development of liver-related complications, and assessing treatment response are crucial. The advantage of simple fibrosis scores lies in their widespread accessibility through routinely performed blood tests and extensive validation in different clinical settings. They have shown reasonable accuracy in diagnosing advanced fibrosis and good performance in excluding the majority of patients with a low risk of liver-related complications. Among patients with elevated serum fibrosis scores, a more specific fibrosis and imaging biomarker has proved useful to accurately identify patients at risk of liver-related complications. Among specific fibrosis blood biomarkers, enhanced liver fibrosis is the most widely utilized and has been approved in the United States as a prognostic biomarker. For imaging biomarkers, the availability of vibration-controlled transient elastography has been largely improved over the past years, enabling the use of liver stiffness measurement (LSM) for accurate assessment of significant and advanced fibrosis, and cirrhosis. Combining LSM with other routinely available blood tests enhances the ability to diagnose at-risk metabolic dysfunction-associated steatohepatitis and predict liver-related complications, some reaching an accuracy comparable to that of liver biopsy. Magnetic resonance imaging-based modalities provide the most accurate quantification of liver fibrosis, though the current utilization is limited to research settings. Expanding their future use in clinical practice depends on factors such as cost and facility availability.
Citations
Citations to this article as recorded by
Effect of Antidiabetic Drug Classes on the Risk of Liver-Related Events in Individuals With T2D and MASLD Yu Shi, Seung Up Kim, Terry Cheuk-Fung Yip, Emmanuel Tsochatzis, Salvatore Petta, Atsushi Nakajima, Hannes Hagström, Elisabetta Bugianesi, Wah-Kheong Chan, Jérôme Boursier, Boon-Bee George Goh, Arun J. Sanyal, Manuel Romero-Gomez, José Luis Calleja, Victo Clinical Gastroenterology and Hepatology.2026; 24(3): 723. CrossRef
Correspondence to editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease” Hye Won Lee, Seung Up Kim Clinical and Molecular Hepatology.2026; 32(1): e87. CrossRef
Fe-Mn-IGF-AMD nanoparticles in accurate detection and treatment of liver cirrhosis via regulating relaxation coefficients and attenuating hepatocyte senescence Baihe Wang, Tingting Ji, Zihao Zhang, Yuyao Duan, Zhiqun Xing, Jiazhi Duan, Songbo Zhao, Yang Jia, Qian Wang Colloids and Surfaces B: Biointerfaces.2026; 257: 115182. CrossRef
Stimuli-responsive nanomedicines for hepatic diseases: mechanism, design, recent advances, and clinical translation Leyi Wang, Xue Zhang, Yinggang Li, Min Zhao, Gang Xu, Zhenyu Duan, Qiyong Gong, Kui Luo Journal of Controlled Release.2026; 390: 114522. CrossRef
Genetic Variants in Liver Cirrhosis: Classifications, Mechanisms, and Implications for Clinical Practice Roshni Pushpa Raghavan, Kirti Theresa Alexander, Shine Sadasivan, Chetan Parmar, Manikandan Kathirvel Journal of Personalized Medicine.2026; 16(1): 29. CrossRef
Risk stratification for hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: Editorial on “High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic Ho Soo Chun, Minjong Lee Clinical and Molecular Hepatology.2026; 32(1): 368. CrossRef
Prognostic value of non-invasive fibrosis assessment scores in predicting mortality among individuals with metabolic dysfunction-associated steatotic liver disease Lingjie Wu, Shunling Cai, Zhongbin Lin, Ruilie Chen, Yuanfeng Zhang, Xiaobing Gong BMC Public Health.2026;[Epub] CrossRef
Liver Stiffness Measured by Vibration-Controlled Transient Elastography Predicts Hepatic Decompensation in Patients with Hepatocellular Carcinoma Receiving Systemic Treatments Jaejun Lee, Hyun Yang, Si Hyun Bae, Hee Sun Cho, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Keungmo Yang, Heechul Nam, Chang Wook Kim, Hae Lim Lee, Hee Yeon Kim, Sung Won Lee, Ahlim Lee, Do Seon Song, Seok Hwan Kim, Myung Jun Song, Soon Kyu Lee, Jung H Liver Cancer.2026; : 1. CrossRef
The prognostic significance of cholesterol, high-density lipoprotein and glucose (CHG) index in evaluating all-cause mortality risk in metabolic dysfunction-associated steatotic liver disease (MASLD) individuals: evidence from two cohort studies Jicai Wang, Guangjie Tu, Qiang Tao, Ruixi Li, Hang Zhai, Shengjie Hong, Xianjie Shi, Guangquan Zhang Cardiovascular Diabetology.2026;[Epub] CrossRef
Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach Beom Kyung Kim The Kaohsiung Journal of Medical Sciences.2026;[Epub] CrossRef
Prediction of major liver-related events in the population using prognostic models Fredrik Åberg, Ville Männistö Gastroenterology Report.2025;[Epub] CrossRef
Clinical and Economic Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Spanish Mediterranean Region: A Population-Based Study Javier Díaz Carnicero, Inma Saurí-Ferrer, Josep Redon, Jorge Navarro, Gonzalo Fernández, Carlos Hurtado, Karine Ferreira, Carolina Alvarez-Ortega, Antón Gómez, Carlos J. Martos-Rodríguez, David Martí-Aguado, Desamparados Escudero, Marta Cedenilla Journal of Clinical Medicine.2025; 14(7): 2441. CrossRef
Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease Jimmy Che-To Lai, Boyu Yang, Hye Won Lee, Huapeng Lin, Emmanuel A Tsochatzis, Salvatore Petta, Elisabetta Bugianesi, Masato Yoneda, Ming-Hua Zheng, Hannes Hagström, Jerome Boursier, Jose Luis Calleja, George Boon-Bee Goh, Wah-Kheong Chan, Rocìo Gallego-Du Gut.2025; 74(12): 2050. CrossRef
Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease Hye Won Lee, Jae Seung Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Clinical and Molecular Hepatology.2025; 31(3): 1018. CrossRef
Non-invasive tests of fibrosis in the management of MASLD: revolutionising diagnosis, progression and regression monitoring Gong Feng, Vincent Wai-Sun Wong, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng Gut.2025; 74(10): 1741. CrossRef
Relative change rate of liver stiffness measurements predicts the risk of liver decompensation in compensated advanced chronic liver disease Yanqiu Li, Zihang Qiao, Jinze Li, Bingbing Zhu, Yu Lu, Ying Feng, Xianbo Wang Clinical and Experimental Medicine.2025;[Epub] CrossRef
Endohepatology in the Management of Liver Diseases Thomas J. Wang, Ajaypal Singh Seminars in Liver Disease.2025; 45(04): 439. CrossRef
Letter to the Editor: Are we overestimating LSM-based HCC risk in MASLD? Addressing immortal time bias Heechul Nam, Sung Won Lee Hepatology.2025;[Epub] CrossRef
Liver stiffness measurement-based risk score for predicting liver decompensation risk: a single-center retrospective Chinese study Yanqiu Li, Zihang Qiao, Jinze Li, Yongqi Li, Ying Feng, Xianbo Wang Clinical and Experimental Medicine.2025;[Epub] CrossRef
Liver Transplantation in the Era of Metabolic Dysfunction–Associated Fatty Liver Disease: Challenges, Ethical Dilemmas, and Future Directions Said A. Al-Busafi, Mohammed Eslam Transplantology.2025; 6(4): 35. CrossRef
Prevalence of MASLD and fibrosis assessed by transient elastography in U.S. adolescents: insights from NHANES 2017-2023 Jialin Wu, Junlong Huang, Shiyu Cao, Yang Lyu, Peiyao Yu, Tiejun Feng, Bonan Chen, Fuda Xie, Ge Zhang, Kangmin Zhuang, Aimin Li, Ka Fai To, Wei Kang Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
Preface Seung Up Kim Clinical and Molecular Hepatology.2024; 30(Suppl): S3. CrossRef
Artificial intelligence (AI)-enabled thermochemical risk modeling via self-attentive deep neural networks for predicting the SADT of organic peroxides Fanzhi Meng, Wei Xu, Yanan Qian, Feng Sun, Bing Sun, Zhe Yang Journal of Loss Prevention in the Process Industries.2026; 99: 105827. CrossRef
Correspondence to letter to the editor 2 on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma” Chun-Ting Ho, Elise Chia-Hui Tan, Chien-Wei Su Clinical and Molecular Hepatology.2025; 31(1): e101. CrossRef
Prediction Model for Familial Aggregated HBV‐Associated Hepatocellular Carcinoma Based on Serum Biomarkers Linmei Zhong, Guole Nie, Qiaoping Wu, Honglong Zhang, Haiping Wang, Jun Yan Cancer Reports.2025;[Epub] CrossRef
Correspondence to editorial on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma” Chun-Ting Ho, Elise Chia-Hui Tan, Chien-Wei Su Clinical and Molecular Hepatology.2024; 30(4): 1016. CrossRef
Huapeng Lin, Grace Lai-Hung Wong, Xinrong Zhang, Terry Cheuk-Fung Yip, Ken Liu, Yee Kit Tse, Vicki Wing-Ki Hui, Jimmy Che-To Lai, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong
Clin Mol Hepatol 2022;28(1):77-90. Published online November 5, 2021
Background/Aims We aimed to determine the association between blood urea level and incident cirrhosis, hepatic decompensation, and hepatocellular carcinoma in chronic liver disease (CLD) patients.
Methods The association between blood urea level and liver fibrosis/liver-related events were evaluated on continuous scale with restricted cubic spline curves based on generalized additive model or Cox proportional hazards models. Then, the above associations were evaluated by urea level within intervals.
Results Among 4,282 patients who had undergone liver stiffness measurement (LSM) by transient elastography, baseline urea level had a U-shaped association with LSM and hepatic decompensation development after a median follow-up of 5.5 years. Compared to patients with urea of 3.6–9.9 mmol/L, those with urea ≤3.5 mmol/L (adjusted hazard ratio [aHR], 4.15; 95% confidence interval [CI], 1.68–10.24) and ≥10 mmol/L (aHR, 5.22; 95% CI, 1.86–14.67) had higher risk of hepatic decompensation. Patients with urea ≤3.5 mmol/L also had higher risk of incident cirrhosis (aHR, 3.24; 95% CI, 1.50–6.98). The association between low urea level and incident cirrhosis and hepatic decompensation was consistently observed in subgroups by age, gender, albumin level, and comorbidities. The U-shaped relationship between urea level and LSM was validated in another population screening study (n=917). Likewise, urea ≤3.5 mmol/L was associated with a higher risk of incident cirrhosis in a territory-wide cohort of 12,476 patients with nonalcoholic fatty liver disease at a median follow-up of 9.9 years (aHR, 1.27; 95% CI, 1.03–1.57).
Conclusions We identified a U-shaped relationship between the urea level and liver fibrosis/incident cirrhosis/hepatic decompensation in patients with CLD.
Citations
Citations to this article as recorded by
An RFH-NPT-based nomogram for predicting the long-term survival of liver cirrhosis patients: a multicenter study Chengbin Zhu, Yuchao Wu, Fulian Zhao, Ruojing Wang, Qijuan Zang, Zhe Jiao, Yage Zhu, Taotao Yan, Juan Du, Li Zhu, Weimin Li, Yongqin Li, Qing Fan, Anping Wu, Xiaodan Liu, Dianzu Liu, Xianmei Tang, Xiaoxiao Xu, Huaying Liao, Yu Li, Yingren Zhao, Yingli He, European Journal of Clinical Nutrition.2026; 80(1): 87. CrossRef
Advances in Electrochemical Urea Biosensors: Trends and Future Prospects Samar Shurbaji, Arshad Khan, Mohammad K. Hassan, Amine Bermak, Wen‐Di Li, Kabir H Biswas, Bo Wang Advanced Sensor Research.2026;[Epub] CrossRef
A dual-purpose paper-based electrochemical device for enzyme-free sensing of urinary urea and micro-powering applications: towards self-powered electrochemical sensors Madhuvallika Sreekonda, Sohel Samad Chaus, Sweta Lal Microchemical Journal.2026; 225: 118076. CrossRef
Preclinical studies on the antitumor and non‐toxic effect of combining pirfenidone with vinorelbine and carboplatin in non‐small cell lung cancer Helena Branco, Catarina A. Rodrigues, Júlio Oliveira, Nuno Mendes, Catarina Antunes, Irina Amorim, Lúcio L. Santos, M. Helena Vasconcelos, Cristina P. R. Xavier International Journal of Cancer.2025; 156(9): 1756. CrossRef
Phase-dependent hepatotoxicity of Aluminum oxide nanoparticles mediated through the intestinal microbiota Mingshu Li, Fuchang Deng, Li Dong, Xiaona Wang, Haiyan Jiang, Siyu Yao, Yuanyuan Chen, Lian Duan, Huamao Du, Guangqiu Qin, Song Tang Environment International.2025; 198: 109398. CrossRef
Parenclitic network mapping predicts survival in critically ill patients with sepsis Emily Ito, Tope Oyelade, Matthew Wikner, Jinyuan Liu, Watjana Lilaonitkul, Ali R. Mani Physiological Reports.2025;[Epub] CrossRef
The role of urea in pathological conditions O.B. Kvasnytska, A.I. Gozhenko, D.D. Ivanov, O.O. Popadynets KIDNEYS.2025; 14(3): 251. CrossRef
Colchicine induces developmental defects and renal toxicity in zebrafish by upregulating the oxidative stress Fang Chen, Haiyan Wei, Dalong Liao, Yong Huang, Yijian Chen, Huiqiang Lu, Rong Xu Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology.2025; 298: 110328. CrossRef
Neurological alterations in adult female rats developmentally exposed to a glyphosate-based herbicide: Potential role of the immune system Cristina Eugenia Gallegos, Mariana Bartos, Fernanda Gumilar, Diego Nicolás Nabaes Jodar, Ileana Lencinas, Cristina Bras, Betina Noemí García, Jorge Andrés Delbés, Sergio Dominguez, Carlos Javier Baier Toxicology.2025; 518: 154279. CrossRef
Inverse Association Between METS-IR and Lung Cancer Risk: The Role of BMI in a Nationwide Korean Cohort Bo-Kyung Shine, In Hwa Jeong, Minkook Son, Bongjo Kim, Sang Yi Moon, Jong Yoon Lee, Hye Ryeon Kim, Seok Jae Huh Cancers.2025; 17(23): 3727. CrossRef
ULTRASONOGRAPHIC INDICATORS OF THE KIDNEYS IN COMBINED LIVER AND KIDNEY PATHOLOGY IN DOGS V. Rudyashko Scientific and Technical Bulletin оf State Scientific Research Control Institute of Veterinary Medical Products and Fodder Additives аnd Institute of Animal Biology.2025; 26(2): 216. CrossRef
Cross-sectional and longitudinal associations between fatty liver index and kidney function using updated MASLD and CKD–EPI 2021 definitions: a population-based study with region-specific cutoffs Sina Bazmi, Mohammadreza Fardaei, Reza Homayounfar, Maryam Kazemi, Babak Pezeshki, Reza Malekzadeh, Nasrollah Ghahramani, Mojtaba Farjam European Journal of Medical Research.2025;[Epub] CrossRef
Comparison of Engineered Liver 3D Models and the Role of Oxygenation for Patient‐Derived Tumor Cells and Immortalized Cell Lines Cocultured with Tumor Stroma in the Detection of Hepatotoxins Mona Mansouri, Astha Lamichhane, Dola Das, Federico Aucejo, Hossein Tavana, Nic D. Leipzig Advanced Biology.2024;[Epub] CrossRef
The Role and Limitations of the Reference Interval Within Clinical Chemistry and Its Reliability for Disease Detection Nathan E. Timbrell British Journal of Biomedical Science.2024;[Epub] CrossRef
The Role of Interleukin-6 and Procalcitonin in Kidney Patients have Bacterial and Viral Infection Anwar Aiad Gaber, Jawad Kadhum Muraih Biomedical and Pharmacology Journal.2024; 17(1): 461. CrossRef
Investigation of the effects of Theranekron and Sorafenib treatments on carcinogenesis, apoptosis and biochemical profile in hepatocellular carcinoma in rats Serdar Vanli, Firuze Kurtoglu, Beyza S. Alan, Gokhan Akcakavak, Ozgur Ozdemir Toxicology Mechanisms and Methods.2024; 34(7): 750. CrossRef
Association of blood urea nitrogen with all-cause and cardiovascular mortality in hyperlipidemia: NHANES 1999–2018 Jing Shen, Zhen Wang, Yong Liu, Tao Wang, Xiao-Yu Wang, Xin-Hui Qu, Zhi-Ping Chen, Xiao-Jian Han Lipids in Health and Disease.2024;[Epub] CrossRef
Association between serum vitamin D status and severity of liver cirrhosis: implications for therapeutic targeting in Nigerian patients Winnifred Njideka Adiri, Bruno Basil, Chinwe Philomena Onyia, Promise Asogwa, Oluchi Joy Ugwuanyi, Olive Obienu, Uchenna Nkemdilim Ijoma, Slyvester Chuks Nwokediuko BMC Gastroenterology.2024;[Epub] CrossRef
Age and the relative importance of liver‐related deaths in nonalcoholic fatty liver disease Huapeng Lin, Terry Cheuk‐Fung Yip, Xinrong Zhang, Guanlin Li, Yee‐Kit Tse, Vicki Wing‐Ki Hui, Lilian Yan Liang, Jimmy Che‐To Lai, Stephen Lam Chan, Henry Lik‐Yuen Chan, Grace Lai‐Hung Wong, Vincent Wai‐Sun Wong Hepatology.2023; 77(2): 573. CrossRef
Trends in risk factor control and treatment among patients with non‐alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory‐wide study Xinrong Zhang, Terry Cheuk‐Fung Yip, Yee‐Kit Tse, Vicki Wing‐Ki Hui, Guanlin Li, Huapeng Lin, Lilian Yan Liang, Jimmy Che‐To Lai, Mandy Sze‐Man Lai, Johnny T. K. Cheung, Henry Lik‐Yuen Chan, Stephen Lam Chan, Alice Pik‐Shan Kong, Grace Lai‐Hung Wong, Vinc Alimentary Pharmacology & Therapeutics.2023; 57(10): 1103. CrossRef
Effects of the in-utero dicyclohexyl phthalate and di-n-hexyl phthalate administration on the oxidative stress-induced histopathological changes in the rat liver tissue correlated with serum biochemistry and hematological parameters Duygu Aydemir, Mufide Aydogan-Ahbab, Nurhayat Barlas, Nuriye Nuray Ulusu Frontiers in Endocrinology.2023;[Epub] CrossRef
A comparative multi-level toxicity assessment of carbon-based Gd-free dots and Gd-doped nanohybrids from coffee waste: hematology, biochemistry, histopathology and neurobiology study Halyna Kuznietsova, Natalia Dziubenko, Konstantin Paliienko, Natalia Pozdnyakova, Natalia Krisanova, Artem Pastukhov, Tetiana Lysenko, Marina Dudarenko, Valeriy Skryshevsky, Vladimir Lysenko, Tatiana Borisova Scientific Reports.2023;[Epub] CrossRef
Alcohol consumption and the risk of liver disease: a nationwide, population-based study Sang Yi Moon, Minkook Son, Yeo Wool Kang, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek Frontiers in Medicine.2023;[Epub] CrossRef
Effects of 4G mobile phone radiation exposure on reproductive, hepatic, renal, and hematological parameters of male Wistar rat Rohit Gautam, Sonali Pardhiya, Jay Prakash Nirala, Priyanka Sarsaiya, Paulraj Rajamani Environmental Science and Pollution Research.2023; 31(3): 4384. CrossRef
Is lean non-alcoholic fatty liver disease a distinct entity? Huapeng Lin, Vincent Wai-Sun Wong Hepatology International.2022; 16(2): 254. CrossRef
Reply to: Blood urea better than creatinine in prognosticating post‐TIPS outcomes: Hope or hype? Luisa Fürschuß, Florian Rainer, Angela Horvath, Vanessa Stadlbauer Liver International.2022; 42(7): 1702. CrossRef
Blood urea better than creatinine in prognosticating post‐TIPS outcomes: Hope or hype? Suprabhat Giri, Shivaraj Afzalpurkar, Sunil Kasturi, Dhiraj Agrawal Liver International.2022; 42(7): 1700. CrossRef
Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations Soon Sun Kim, Jae Youn Cheong Clinical and Molecular Hepatology.2022; 28(4): 802. CrossRef
First
Prev
